Wall Street analyst estimates for Delcath Systems, Inc. (DCTH): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects.
Valuation Ratios
| P/E Ratio | 1467.87 |
| Price / Book | 4.78 |
| EV / EBITDA | 297.45 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $2.7M | $3.4M | $1.6M | $1.6M | $3.6M | $2.7M | $2.1M | $37.2M | $85.2M |
| Cost of Revenue | $550000 | $701000 | $1.0M | $719000 | $640000 | $671000 | $686000 | $635000 | $6.2M | $11.8M |
| Gross Profit | $1.4M | $2.0M | $2.4M | $861000 | $1.0M | $2.9M | $2.0M | $1.4M | $31.0M | $73.4M |
| Research & Development | $8.4M | $10.5M | $19.6M | $9.5M | $11.2M | $13.8M | $18.6M | $17.5M | $13.9M | $29.2M |
| Selling, General & Admin | $9.4M | $9.7M | $9.8M | $11.3M | $11.1M | $13.6M | $17.3M | $22.1M | $29.6M | $43.5M |
| Operating Expenses | $17.9M | $20.2M | $29.5M | $20.8M | $22.3M | $27.4M | $35.9M | $39.6M | $43.4M | $72.8M |
| Operating Income | -$16.4M | -$18.2M | -$27.1M | -$19.9M | -$21.3M | -$24.5M | -$33.9M | -$38.2M | -$12.4M | $660000 |
| EBITDA | -$3.3M | -$23.1M | -$10.8M | -$3.9M | -$23.8M | -$24.3M | -$33.7M | -$45.8M | -$26.2M | $3.9M |
| Interest Expense | $14.3M | $21.7M | $8.0M | $4.7M | $175000 | $1.2M | $2.7M | $1.4M | 0 | 0 |
| Pre-tax Income | -$18.0M | -$45.1M | -$19.2M | -$8.9M | -$24.2M | -$25.6M | -$36.5M | -$47.7M | -$26.4M | $3.5M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $810000 |
| Net Income | -$18.0M | -$45.1M | -$19.2M | -$8.9M | -$24.2M | -$25.6M | -$36.5M | -$47.7M | -$26.4M | $2.7M |
| EPS | $-452622931118.73 | $-2275919775.64 | $-503846.14 | $-342.82 | $-8.36 | $-3.59 | $-4.12 | $-0.48 | $-0.11 | $0.08 |
| EPS (Diluted) | $-452622931118.73 | $-2275919775.64 | $-503846.14 | $-342.82 | $-8.36 | $-3.59 | $-4.12 | $-0.48 | $-0.12 | $0.07 |
| Shares Outstanding (Diluted) | $0 | $0 | $38 | $25900 | $2.9M | $7.1M | $8.9M | $16.2M | $28.5M | $39.9M |
Price
| Price | $16.22 |
| Market Cap | $560M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AGL · BWAY · CERS · MASS · NAKA · NPCE · RXST
Explore sector: Healthcare · Medical - Devices
More sections of DCTH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks